{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:02:22Z","timestamp":1755216142233,"version":"3.43.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The aim of this review is to discuss the relationship between cachexia in lung cancer and the role of supportive and palliative care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A recent meta-analysis has shown that early supportive and palliative care improves outcome in patients with lung cancer. This includes benefits in survival, quality of life, mood and need for less aggressive end of life care. However, we examine how this is impacted by cachexia. Cachexia is a pro inflammatory syndrome causing loss of weight, muscle and function. The level of cachexia likely impacts early supportive and palliative care goals for individual patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>It is suggested that supportive and palliative care is a key component of managing patients with lung cancer and should be routine practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000772","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T17:00:28Z","timestamp":1752858028000},"page":"192-197","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the impact of early palliative care intervention in patients with lung cancer, cachexia and weight loss"],"prefix":"10.1097","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9298-7767","authenticated-orcid":false,"given":"Iain","family":"Phillips","sequence":"first","affiliation":[{"name":"Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland"},{"name":"CRUK Cancer Research Centre, University of Edinburgh, Edinburgh, Scotland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Hall","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Stares","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland"},{"name":"CRUK Cancer Research Centre, University of Edinburgh, Edinburgh, Scotland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"R1-20250803","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1136\/bmjspcare-2020-002838","article-title":"Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial","volume":"13","author":"Phillips","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"R2-20250803","doi-asserted-by":"crossref","first-page":"115303","DOI":"10.1016\/j.ejca.2025.115303","article-title":"Four decades of lung cancer: trends in comorbidities and causes of death in a nationwide danish cohort","volume":"218","author":"Borg","year":"2025","journal-title":"Eur J Cancer"},{"key":"R4-20250803","doi-asserted-by":"crossref","first-page":"803\u2013822","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"R5-20250803","doi-asserted-by":"crossref","first-page":"2339\u20132349","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"R6-20250803","doi-asserted-by":"crossref","first-page":"1301\u20131311","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"R7-20250803","doi-asserted-by":"crossref","first-page":"688\u2013696","DOI":"10.1016\/j.clon.2019.07.020","article-title":"Stage III non-small cell lung cancer management in England","volume":"31","author":"Adizie","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R9-20250803","doi-asserted-by":"crossref","first-page":"100282","DOI":"10.1016\/j.advnut.2024.100282","article-title":"Prevalence of and survival with cachexia among patients with cancer: a systematic review and meta-analysis","volume":"15","author":"Takaoka","year":"2024","journal-title":"Adv Nutr"},{"key":"R12-20250803","doi-asserted-by":"crossref","first-page":"e1373","DOI":"10.1093\/oncolo\/oyae050","article-title":"Early incorporation to palliative care (EPC) in patients with advanced non-small cell lung cancer: the PACO randomized clinical trial","volume":"29","author":"Allende","year":"2024","journal-title":"Oncologist"},{"key":"R13-20250803","doi-asserted-by":"crossref","first-page":"10499091241300530","DOI":"10.1177\/10499091241300530","article-title":"Early palliative care in advanced non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Liu","year":"2024","journal-title":"Am J Hosp Palliat Care"},{"key":"R14-20250803","doi-asserted-by":"crossref","first-page":"2336\u20132357","DOI":"10.1200\/JCO.24.00542","article-title":"Palliative care for patients with cancer: ASCO guideline update","volume":"42","author":"Sanders","year":"2024","journal-title":"J Clin Oncol"},{"key":"R15-20250803","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO clinical practice guidelines","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"key":"R16-20250803","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R17-20250803","doi-asserted-by":"crossref","first-page":"2438\u20132453","DOI":"10.1200\/JCO.20.00611","article-title":"Management of cancer cachexia: ASCO guideline","volume":"38","author":"Roeland","year":"2020","journal-title":"J Clin Oncol"},{"key":"R18-20250803","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/cancers16081508","article-title":"Prognostic biomarkers of systemic inflammation in non-small cell lung cancer: a narrative review of challenges and opportunities","volume":"16","author":"Stares","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R19-20250803","doi-asserted-by":"crossref","first-page":"853\u2013867","DOI":"10.1002\/jcsm.13491","article-title":"Biomarker endpoints in cancer cachexia clinical trials: systematic review 5 of the cachexia endpoint series","volume":"15","author":"Yule","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R20-20250803","doi-asserted-by":"crossref","first-page":"489\u2013495","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R21-20250803","doi-asserted-by":"crossref","first-page":"97\u2013104","DOI":"10.1634\/theoncologist.2017-0255","article-title":"Sarcopenia is associated with quality of life and depression in patients with advanced cancer","volume":"23","author":"Nipp","year":"2018","journal-title":"Oncologist"},{"key":"R22-20250803","doi-asserted-by":"crossref","first-page":"89\u201394","DOI":"10.1007\/s13539-014-0142-1","article-title":"Psychosocial impact of cancer cachexia","volume":"5","author":"Hopkinson","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R23-20250803","doi-asserted-by":"crossref","first-page":"13\u201320","DOI":"10.1038\/s41366-024-01642-z","article-title":"Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis","volume":"49","author":"Zhang","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"R24-20250803","doi-asserted-by":"crossref","first-page":"1932\u20131948","DOI":"10.1002\/jcsm.13321","article-title":"Physical function endpoints in cancer cachexia clinical trials: systematic review 1 of the cachexia endpoints series","volume":"14","author":"McDonald","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R25-20250803","first-page":"102360","article-title":"Validation of the Scottish Immunotherapy Prognostic Score (SIPS) in NSCLC patients treated with first-line pembrolizumab","volume":"16","author":"Gomez-Randulfe Rodriguez","year":"2024","journal-title":"Cancers"},{"key":"R26-20250803","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0169-5002(21)00301-9","article-title":"Scottish immunotherapy prognostic score: biomarker of systemic inflammation predicts response to first line pembrolizumab for metastatic non small cell lung cancer","volume":"156","author":"Ding","year":"2021","journal-title":"Lung Cancer"},{"key":"R27-20250803","doi-asserted-by":"crossref","first-page":"107497","DOI":"10.1016\/j.lungcan.2024.107497","article-title":"Prognostic value of the scottish inflammatory prognostic score in patients with NSCLC expressing PD-L1 \u2265 50 % progressing on first-line pembrolizumab","volume":"189","author":"Stares","year":"2024","journal-title":"Lung Cancer"},{"key":"R28-20250803","doi-asserted-by":"crossref","first-page":"154\u2013160","DOI":"10.1097\/SPC.0000000000000716","article-title":"A traffic light approach for treatment and supportive care stratification in lung cancer","volume":"18","author":"Phillips","year":"2024","journal-title":"Curr Opin Support Palliat Care"},{"key":"R31-20250803","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/spcare-2024-004869","article-title":"Early prehabilitation reduces admissions and time in hospital in patients with newly diagnosed lung cancer","volume":"15","author":"Phillips","year":"2024","journal-title":"BMJ Support Palliat Care"},{"key":"R32-20250803","doi-asserted-by":"crossref","first-page":"e908","DOI":"10.1136\/spcare-2023-004349","article-title":"Early prehabilitation in suspected locally advanced and metastatic lung cancer","volume":"13","author":"Phillips","year":"2023","journal-title":"BMJ Support Palliat Care"},{"key":"R33-20250803","doi-asserted-by":"crossref","first-page":"s72","DOI":"10.1016\/S0169-5002(23)00592-5","article-title":"The added value of screening for nutritional impact symptoms at the time of the new patient respiratory clinic for patients with suspected lung cancer","volume":"178","author":"Maguire","year":"2023","journal-title":"Lung Cancer"},{"key":"R34-20250803","first-page":"CD015749","article-title":"Multimodal interventions for cachexia management","volume":"3","author":"Reid","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"R35-20250803","doi-asserted-by":"crossref","first-page":"519\u2013531","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"R36-20250803","doi-asserted-by":"crossref","first-page":"2291\u20132303","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N Engl J Med"},{"key":"R37-20250803","doi-asserted-by":"crossref","first-page":"e13732","DOI":"10.1002\/jcsm.13732","article-title":"Anamorelin efficacy in non-small-cell lung cancer patients with cachexia: insights from ROMANA 1 and ROMANA 2","volume":"16","author":"Laird","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R38-20250803","doi-asserted-by":"crossref","first-page":"2371\u20132373","DOI":"10.1056\/NEJMe2411741","article-title":"Ponsegromab for cancer cachexia - a new dawn for an old condition?","volume":"391","author":"Laird","year":"2024","journal-title":"N Engl J Med"},{"key":"R39-20250803","doi-asserted-by":"crossref","first-page":"258\u2013265","DOI":"10.1136\/bmjspcare-2017-001440","article-title":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","volume":"8","author":"Solheim","year":"2018","journal-title":"BMJ Support Palliat Care"},{"key":"R40-20250803","doi-asserted-by":"crossref","first-page":"17511437251324054","DOI":"10.1177\/17511437251324054","article-title":"Withdrawal of life sustaining therapies for awake patients in critical care: the benefits of a collaborative intensivist & palliative care approach","volume":"26","author":"Edwardson","year":"2025","journal-title":"J Intensive Care Soc"},{"key":"R41-20250803","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bmj.p1531","article-title":"Consent consensus: time for national standard consent forms as an aid to robust consent","volume":"382","author":"Kenney-Herbert","year":"2023","journal-title":"BMJ"},{"key":"R43-20250803","doi-asserted-by":"crossref","first-page":"e2986","DOI":"10.1136\/spcare-2022-003789","article-title":"Palliative care integration in the intensive care unit: healthcare professionals\u2019 perspectives - a qualitative study","volume":"14","author":"Poi","year":"2024","journal-title":"BMJ Support Palliat Care"},{"key":"R44-20250803","doi-asserted-by":"crossref","first-page":"681\u2013682","DOI":"10.1001\/jamaoncol.2021.8210","article-title":"Palliative care is the umbrella, not the rain-a metaphor to guide conversations in advanced cancer","volume":"8","author":"Zimmermann","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T20:09:16Z","timestamp":1754251756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000772","relation":{},"ISSN":["1751-4266"],"issn-type":[{"type":"electronic","value":"1751-4266"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}